Recent Updates
Recently added Catalysts
LUCD Positive Sentiment Score: 70/100

Lucid Diagnostics to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 26, 2026

Key Takeaway: Lucid Diagnostics Inc. will hold a business update conference call on March 26, 2026, at 8:30 AM ET. CEO Lishan Aklog and CFO Dennis McGrath will discuss the company's operations and fourth quarter 2025 financial results. The event will be accessible via webcast and telephone for investors.

Market Sentiment Analysis

POSITIVE FACTORS

  • Lucid Diagnostics is hosting a business update conference call.
  • The company is focused on cancer prevention and early detection.
  • Key executives will discuss growth strategies and financial results.

Full Press Release Details

Conference Call and Webcast at 8:30 AM ET
NEW YORK,March 12, 2026/PRNewswire/ --Lucid Diagnostics Inc.(Nasdaq:LUCD)("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq:PAVM), today announced that it will host a business update conference call and webcast on Thursday, March 26, 2026, at 8:30 AM ET. During the call,Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update and discuss the Company's operations and growth strategy. In addition,Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's fourth quarter 2025 financial results.
The webcast will be available at the investor relations section of the Company's website atluciddx.com.  Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "Lucid Diagnostics Business Update" to join.
Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website atluciddx.com.

About Lucid Diagnostics

Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq:PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid'sEsoGuard®Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with itsEsoCheck®Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.
For more information, please visitwww.luciddx.comand for more information about its parent company PAVmed, please visitwww.pavmed.com.
SOURCE Lucid Diagnostics

Frequently Asked Questions

When is the Lucid Diagnostics business update call?

The business update call is scheduled for March 26, 2026, at 8:30 AM ET.

Who will present during the conference call?

CEO Lishan Aklog and CFO Dennis McGrath will present during the call.

How can I access the conference call?

Listeners can join via telephone or webcast on the company's investor relations website.

What will be discussed in the business update?

The call will cover the company's operations, growth strategy, and Q4 2025 financial results.

Last updated: Mar 12, 2026